Navigation Links
Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
Date:6/19/2012

CRANBURY, N.J., June 19, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that a Phase I clinical trial being conducted by AstraZeneca of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for the treatment of obesity, has been halted. AZD2820 is a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies.

The Phase 1 clinical trial of AZD2820 was halted by the Safety Review Committee established by AstraZeneca after meeting a predefined stopping criterion. The stopping criterion was a serious adverse event. It is suspected that the subject may have had an allergic reaction following his first dose. The subject was treated at the clinical site and has fully recovered. A review and investigation of the incident has commenced.

"We are pleased that the subject has fully recovered from this unfortunate adverse event and we will work closely with our partner AstraZeneca to investigate the cause of this incident and the overall plans for the AZD2820 program," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "AstraZeneca has confirmed their remaining commitment to the continued advancement of melanocortin agonists for treatment of obesity, including a number of collaboration compounds in various stages of preclinical testing."

The phase I single center study, conducted by AstraZeneca, targeted enrolling 72 obese but otherwise healthy male subjects, with a body mass index between 30 and 35 kg/m2, in a randomized, single-blind, placebo-controlled, trial. Eleven subjects had completed their dosing regimen prior to the halting of the trial. The primary outcome of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD2820 after administration of multiple ascending doses. Another Phase 1 single ascending dose study of AZD2820 was finalize
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
2. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
3. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
4. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
5. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
6. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
7. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
8. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
9. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
10. OrthoAccel Technologies, Inc. Names U.S. National Sales Director
11. Metamaterials, quantum dots show promise for new technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading ... unaudited financial results for the fourth quarter and full ... 2014 Financial Highlights(Compared to the fourth quarter 2013) ... of 11.4% from $22.9 million in the prior year ... pandemic influenza vaccine of $0.1 million in the fourth ...
(Date:4/20/2015)... Global Stem Cells Group today announced ... gathering of aesthetic medicine experts and innovators. GSCG Advisory ... the company’s brand new training course that combines facial ... , The course is designed to address the ... including facial aging caused by volume loss. , ...
(Date:4/18/2015)... PHILADELPHIA , April 18, 2015 ... (NASDAQ: CRIS ) will be presenting data ... the American Associate of Cancer Research Annual Meeting ... ).      (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) ... its proprietary Nicotinamide phosphoribosyltransferase (NAMPT) small molecule inhibitors ...
(Date:4/17/2015)... 2015 Reed Technology and Information ... data management, preparation, and submission to the U.S. Food ... a new Lot Distribution Report (LDR) service for manufacturers ... compliant with the FDA’s new rule on electronic submission ... monitor the volume and timing of particular biologics introduced ...
Breaking Biology Technology:Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3
... day that a research scientist and university professor gets to see ... few months, Richard W. Siegel will get to watch his name ... a new title that seems light years away from laboratory benches ... MAX," has been a three-year labor of love for Siegel. From ...
... IN KEY GLOBAL MARKETS, RANCHO CORDOVA, Calif., ... a leading supplier of innovative products and,services that ... it has signed,a distribution agreement with Celling Technologies ... stem cells from bone,marrow. The distribution rights are ...
... Sept. 9 For the second consecutive,year, MedNet ... study management systems, has been recognized by,Inc. magazine ... private,organizations. With consistently strong growth over the past ... in the Twin Cities,metro area, and fifth among ...
Cached Biology Technology:Professor-turned-producer learns the movie biz 2Professor-turned-producer learns the movie biz 3Professor-turned-producer learns the movie biz 4Professor-turned-producer learns the movie biz 5ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device 2ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device 3ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device 4MedNet Solutions Again Recognized as one of the Fastest Growing US Companies 2
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... ceremony at Oslo Concert Hall, seven pioneering researchers in ... as the first Kavli Prize laureates, receiving a gold ... Haakon Magnus. Joining His Royal Highness Crown ... of Science and Letters, the Ministry of Research of ...
... 17 September, in the context of France,s presidency of ... 2008, at the Grand Palais. The GMES (Global ... up to provide services relating to the environment, climate ... draw on data - mainly Earth observation data - ...
... test to detect whether a person might develop Alzheimer,s ... in their quest toward reversing the disease,s onset in ... Building on a study that started 20 years ago ... or in various stages of developing Alzheimer,s disease, the ...
Cached Biology News:Inaugural Kavli laureates honored in Oslo ceremony 2Major European program for the environment under the spotlight in Lille, France 2Researchers seeking to identify Alzheimer's risk focus on specific blood biomarker 2
... for stabilizing 50g of purified RNA samples for ... delivers all of the advantages and applications you ... the RNA can be used for enzymatic applications ... has been optimised for the stabilization of aqueous ...
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Plasmid expressing Zeocin resistance gene....
Biology Products: